BRCA1 and neoplasm: Based on currently available data, patients with PD-L1-positive mTNBC are candidates to receive first-line nab–paclitaxel–atezolizumab, regardless of germline BRCA1/2 status; patients with germline mutations in BRCA1/2 genes and PD-L1-negative neoplasms by IHC are candidates to receive first-line olaparib/talazoparib; finally, patients with PD-L1-negative tumors and wild-type BRCA1/2 status are candidates to receive standard chemotherapy (either single-agent or combination chemotherapy).